2023
Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors
Wang Y, Lu L, Ling C, Zhang P, Han R. Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors. Nutrients 2023, 15: 3984. PMID: 37764768, PMCID: PMC10537481, DOI: 10.3390/nu15183984.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsPD-1/PD-L1 inhibitorsPD-L1 inhibitorsICI therapyDietary interventionBC patientsBreast cancerTherapeutic strategiesNovel immune checkpoint inhibitorsHDAC2 inhibitorsIntegrated therapeutic strategiesOptimal clinical benefitKaplan-Meier plotter platformNew therapeutic strategiesAnti-cancer effectsCheckpoint inhibitorsSupportive therapyClinical benefitHigh morbidityCombination therapyTreatment outcomesLethal malignancyTherapeutic effectEffective treatmentPrognostic analysis
2022
Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer
Han R, Yang H, Li Y, Ling C, Lu L. Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer. Medical Oncology 2022, 39: 213. PMID: 36175803, PMCID: PMC9522682, DOI: 10.1007/s12032-022-01814-9.Peer-Reviewed Original ResearchConceptsProstate cancer cellsProstate cancerHDAC3 inhibitorCancer cellsCancer-related deathAnti-cancer effectsVivo mouse modelAnti-cancer efficacyAnti-cancer activityMouse modelNew agentsSecond causeHDAC inhibitorsCancerNormal cellsInhibitorsValeric acidCellsCASP3 activityCulture systemDiseaseChemosensitizers